This study evaluates the genotoxic potential of two Ru(III) complexes with thiosemicarbazone based ligands. The complexes were tested for in vitro protective effect on chromosome aberrations in peripheral human lymphocytes using the cytokinesis block micronucleus (CBMN) assay at concentrations 1.5; 3.7 and 7.4 µg/mL. The cell culture treated with the tested complexes, at 3.7 µg/mL concentration, decreased a frequency of micronucleus for 37% and 32%, when compared with the control cell cultures. At concentration of 7.4 (1.5) µg/mL of this complexes exhibited slightly lower effect of micronucleus for 30% (35%) and 27% (29%), when compared with the control cell cultures.
INTRODUCTION
Metal complexes stay a significant resource for creating chemical diversity in the fields of biological, pharmaceutical and medicinal chemistry as antitumor and antimicrobial agents [1] [2] [3] . For this purpose, a large number of these complexes are synthesized and intensively investigated [4] [5] [6] . In the pre-clinical studies, the biological properties of the potential drug should be thoroughly investigated in order to obtain as much information as possible about its therapeutic and undesirable effects in the living organism 7 . Thiosemicarbazone and their metal complexes are of huge importance as they possess an abundant variety of biological properties including antibacterial, antifungal, antitumor, antiviral, anti malarial activities [8] [9] [10] [11] [12] [13] . The chemistry and pharmacological applications of ruthenium thiosemicarbazone complexes have been extensively studied [14] [15] [16] [17] [18] [19] . The complexes of Ru(III) with thiosemicarbazone based ligands exhibited in vitro antitumor activity against MCF-7 tumor cells, significant antiproliferative activities on human lymphocyte culture and inhibitory effects on lung carcinoma A549 cells 20, 21 . The synthesis of ruthenium dibasic tridentate thiosemicarbazones complexes with ONS donors are of great significance because of their wide range of medicinal activities 22 . The analysis of micronuclei (MN) in cultured lymphocytes is increasingly applied as a method to biomonitor human exposure to genotoxic agents, largely because the cytokinesis block (CB) technique, has made it possible to identify cells that have divided once in culture (second cycle interphase cells division. The simplicity of scoring and the wide applicability of the in vitro micronucleus test in different cell types make it an attractive tool to assess cytogenetic abnormality 23 . Micronuclei are efficiently expressed in dividing cells when chromosome breaks are induced by peroxyl radicals. The induced chromosome breaks lag behind at anaphase in dividing cells and are subsequently packaged within nuclear membranes to produce micronucleus. Micronucleus (MN) expression in peripheral blood lymphocytes is well established as a method to monitor chromosome damage in human populations. The analysis of MN in cultured lymphocytes is increasingly applied as a method to biomonitor human exposure to genotoxic agents largely because the cytokinesis block (CBMN) technique has made it possible to identify cells that have divided once in culture (second cycle interphase cells) 24 .
In our previous paper, we showed synthesis and characterization of the Ru(III) complexes of the type Na[RuL2] (where L = dibasic tridentate thiosemicarbazone ligand) 14 . The present article is a continuation of the research activities of the study on in vitro effects of these complexes on human lymphocytes using the CBMN assay.
EXPERIMENTAL

Synthesis of Ligands and Complexes
Thiosemicarbazone ligands and complexes were prepared according to the previously published procedures 14 .5-Cl-salicylaldehyde thiosemicarbazone and 5-Br-salicylaldehyde thiosemicarbazone, hereinafter 5-X-SALTSC (X = Cl, Br) were prepared in reaction of thiosemicarbazide and 5-Xsalicylaldehyde (X = Cl, Br) in the molar ratio 1:1 in absolute ethanol. Complexes of Ru(III) with thiosemicarbazone ligands, hereinafter Na[Ru(5-X-SALTSC-2H)2] (where X = Cl, Br) were prepared in reaction of appropriate thiosemicarbazone ligand and RuCl3 in the molar ratio 2:1 in absolute ethanol.
Subjects
Venous blood samples were obtained using heparinized sterile vacutainers (Becton Dickinson, Bradford, MA) from five healthy non/smoking female volunteers who had not been exposed to chemicals, drugs or other substances. A safety protocol concerning blood/born pathogen/biohazard was taken. The volunteers gave their permission for using their blood for the experiment. From each subject, two aliquots of blood, 5mL each were obtained. The study complied with the code of ethics of the World Medical Association (Helsinki Declaration of 1964, as revised in 2002) 25 . The blood samples were obtained at the Medical Unit in accordance with current Health and Ethical regulations in Serbia, Law on Health Care (2005) 26 .
Cytokinesis-block MN assay
The culture lymphocytes were treated with tested complexes (1.5; 3.7, and 7.4 µg/mL). One cell culture served as the control and isolated complexes were not added in this. One cell culture containing Amifostine WR-2721(98%, S-2[3-aminopropylamino]-ethylphosphothioic acid) at 1.0 µg/mL), (Marligen-Biosciences,USA), was used as a positive control. They were added to the cultures 25 h after phytohaemaglutinin (PHA) stimulation and life until harvest. All cultures were incubated in a thermostat at 37°C. Treatment with the investigated complexes lasted for 19 h, where after all cultures were rinsed with a pure medium, transferred into 5 mL fresh RPMI 1640 medium (RPMI 1640 Medium + GlutaMAX + 25 mM HEPES; Invitrogen-Gibco-BRL, Vienna, Austria) and incubated for additional 72 h. Approximately 2 x 106 blood lymphocytes were set up in 5 mL RPMI-1640 medium supplemented with 15% of calf serum and 2.4 µg/mL of phytohaemaglutinin (Invitrogen-Gibco-BRL). One hour after initiating the cell stimulation, investigated complexes (three concentrations) were added to the samples. The incidence of spontaneously occurring MN in control samples was scored. For MN preparation, the cytokinesis-block method of Fenech and Morley was used with some modifications, as described in Stankovic et al. 23, 27 . At least 1000 binucleated (BN) cells per sample were scored, registering MN according to the criteria of Countryman and Heddle, and Fenech and Morley 28, 23 . Cytochalasin B (Invitrogen-Gibco-BRL, Vienna, Austria) at a final concentration of 6 µg/mL was added to the samples after 44 h of culture, and the lymphocyte cultures were incubated for a further 24 h. After 72 h of culture, the cells were washed with 0.9% NaCl (Merck, Sharp and Dohme GMBH., Vienna, Austria), collected by CYTOKINESIS BLOCK MICRONUCLEUS N. Ljubijankić et al.
centrifugation and treated with a hypotonic solution at 37°C. The hypotonic solution consisted of 0.56% KCl + 0.9% NaCl (mixed in equal volumes). The cell suspension was prefixed in methanol/acetic acid (3:1), washed three times with fixative, and dropped onto a clean slide 23 . The slides were air dried and stained with alkaline Giemsa 2% (Sigma-Aldrich, Vienna, Austria). At least 1000 binucleated (BN) cells per sample were scored, registering MN according to the criteria of Countryman and Heddle and Fenech and Morley 28, 23 . The effects of investigated complexes on cell proliferation were estimated by the cytokinesis-block proliferation index (CBPI), calculated as suggested by Surralles 
Statistics and index calculation
The statistical analysis was performed using Origin software package version 7.0. The statistical significance of the difference between the data pairs was evaluated by analysis of variance (One way ANOVA) followed by the Tukey test. Statistical difference was considered significant at p< 0.01 and p< 0.05. The index calculating is presented as the % of change comparing different groups.
RESULTS AND DISCUSSION
The structures of tested Ru(III) thiosemicarbazone complexes are shown in Fig.-1 . 
The results of Cytokinesis -Block Micronucleus (CBMN)
This article summarized the results of using CBMN assay to evaluate the antioxidant potential of complexes in human lymphocytes. They were associated with DNA repair system inhibitor, aminofostine WR-2721. The complexes were tested for in vitro protective effect on chromosome aberrations in peripheral human lymphocytes using CBMN assay at concentrations of 1.5; 3.7 and 7.4 µg/mL. The frequencies and distribution of MN in human lymphocytes were scored. The results are presented in Table- effect (35% and 30%; p<0.01 and p < 0.05). The complex Na[Ru(5-Cl-SALTSC-2H)2] at a concentration of 3.7 µg/mL also caused significant (p < 0.05), decrease of the MN frequency (32%), but less than former doses, when compared with the control cell cultures. The concentration of 1.5 and 7.4 µg/mL of this complex exhibited decreasing the significant (p<0.05) frequency of MN by (29% and 27%) when compared with the control cell cultures. The frequency of MN is statistically significant (p < 0.05) between cell cultures treated with amifostine (1 µg/mL) and cell cultures treated with complexes Na[Ru(5-Cl-SALTSC-2H)2] and Na[Ru(5-Br-SALTSC -2H)2] (1.5 µg/mL). The effect of complexes on cell proliferation was investigated by determining the cytokinesis-block proliferation index (CBPI). In this study we found that the lower concentration of complexes possesses beneficial effect on lymphocyte cells culture by decreasing the frequency of MN. Our results provide the evidence of protective effects of tested complexes on cytogenetic and damages in human lymphocytes treated in vitro.
CONCLUSION
Two ruthenium(III) thiosemicarbazide complexes, Na[Ru(5-Cl-SALTSC-2H)2] and Na[Ru(5-Br-SALTSC-2H)2], were tested for antioxidant potential in peripheral human lymphocytes using the CBMN assay. We found that complexes reduced the frequency of MN in concentration-dependent manner and the medium concentration of 3.7 µg/mL was the most effective. This result is important taking into account that synthetic protectors, used in the treatment of humans, decrease the frequency of MN by around 18% (Amifostin WR-2721) 30 .
